HK1052950B - 使用病毒淨化細胞 - Google Patents

使用病毒淨化細胞

Info

Publication number
HK1052950B
HK1052950B HK03105013.9A HK03105013A HK1052950B HK 1052950 B HK1052950 B HK 1052950B HK 03105013 A HK03105013 A HK 03105013A HK 1052950 B HK1052950 B HK 1052950B
Authority
HK
Hong Kong
Prior art keywords
cells
purging
viruses
undesirable
subject invention
Prior art date
Application number
HK03105013.9A
Other languages
English (en)
Other versions
HK1052950A1 (en
Inventor
L Atkins Harold
c bell John
J Heilman Conrad Jr
D Lichty Brian
M Lorence Robert
s roberts Michael
F Stojdl David
Original Assignee
Wellstat Biologics Corp
Univ Ottawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp, Univ Ottawa filed Critical Wellstat Biologics Corp
Publication of HK1052950A1 publication Critical patent/HK1052950A1/xx
Publication of HK1052950B publication Critical patent/HK1052950B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK03105013.9A 2000-06-26 2003-07-11 使用病毒淨化細胞 HK1052950B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21401400P 2000-06-26 2000-06-26
PCT/US2001/041121 WO2002000233A2 (en) 2000-06-26 2001-06-26 Purging of cells using viruses

Publications (2)

Publication Number Publication Date
HK1052950A1 HK1052950A1 (en) 2003-10-03
HK1052950B true HK1052950B (zh) 2005-06-24

Family

ID=22797442

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105013.9A HK1052950B (zh) 2000-06-26 2003-07-11 使用病毒淨化細胞

Country Status (13)

Country Link
US (3) US20020037543A1 (zh)
EP (1) EP1297121B1 (zh)
JP (2) JP5208343B2 (zh)
CN (1) CN1250711C (zh)
AT (1) ATE294858T1 (zh)
AU (2) AU2001279264B2 (zh)
CA (1) CA2412493C (zh)
DE (1) DE60110593T2 (zh)
HK (1) HK1052950B (zh)
IL (2) IL153570A0 (zh)
RU (1) RU2270685C2 (zh)
WO (1) WO2002000233A2 (zh)
ZA (1) ZA200300016B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) * 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR028040A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
CA2412493C (en) * 2000-06-26 2010-11-09 Wellstat Biologics Corporation Purging of cells using viruses
JP4916641B2 (ja) * 2001-05-11 2012-04-18 ウェルスタット バイオロジクス コーポレイション 腫瘍崩壊性ウイルス治療
EP1411880B1 (en) * 2001-07-11 2018-04-25 University of Miami Recombinant vsv for the treatment of tumor cells
CA2575591A1 (en) * 2003-08-08 2005-02-17 Yuji Shino A pharmaceutical composition for treatment of cancers
US20050214266A1 (en) * 2004-03-12 2005-09-29 Oncolytics Biotech Inc. Combination of transplantation and oncolytic virus treatment
US8236298B2 (en) * 2004-08-20 2012-08-07 Viralytics Limited Methods and compositions for treatment of hematologic cancers
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
EP1917351A4 (en) 2005-08-01 2009-12-16 Univ Technologies Int ATTENUATED REOVIRUS
US20100086522A1 (en) * 2006-07-18 2010-04-08 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
US10369171B2 (en) * 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US8481297B2 (en) * 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
ATE539148T1 (de) 2009-11-30 2012-01-15 United Cancer Res Inst Neuer klon des geflügelpestvirus, herstellung und anwendung bei der medizinischen behandlung von krebs
US20130310442A1 (en) * 2010-09-09 2013-11-21 Noxxon Pharma Ag SDF-1 Binding Nucleic Acids and the use Thereof in Cancer Treatment
SG11201504843UA (en) 2012-12-21 2015-07-30 Ottawa Hospital Res Inst Non-replicating virus-derived particles and uses thereof
ES2952055T3 (es) 2015-01-26 2023-10-26 Ottawa Hospital Res Inst Composiciones y métodos para la sensibilización viral
EP3518948B1 (en) 2016-10-03 2023-04-12 Ottawa Hospital Research Institute Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic rna viruses
EP3714044A4 (en) 2017-11-24 2021-11-24 Ottawa Hospital Research Institute COMPOSITIONS AND METHODS FOR IMPROVING THE PRODUCTION, GROWTH, SPREAD OR ONCOLYTIC AND IMMUNOTHERAPEUTIC EFFECTIVENESS OF VIRUSES SENSITIVE TO INTERFERON

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
AU699487B2 (en) 1993-04-30 1998-12-03 Robert M. Lorence Methods of treating and detecting cancer using viruses
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
CN1281336A (zh) * 1997-10-09 2001-01-24 病毒防御公司 使用病毒来治疗赘生物
NZ550861A (en) 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
EP1716858B9 (en) 1999-09-17 2009-08-12 Wellstat Biologics Corporation Oncolytic virus
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
AR028040A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
CA2412493C (en) * 2000-06-26 2010-11-09 Wellstat Biologics Corporation Purging of cells using viruses

Also Published As

Publication number Publication date
DE60110593D1 (de) 2005-06-09
US7192580B2 (en) 2007-03-20
ATE294858T1 (de) 2005-05-15
CN1454254A (zh) 2003-11-05
WO2002000233A3 (en) 2002-08-22
DE60110593T2 (de) 2006-01-19
IL153570A (en) 2009-09-22
CN1250711C (zh) 2006-04-12
US20020037543A1 (en) 2002-03-28
RU2270685C2 (ru) 2006-02-27
WO2002000233A2 (en) 2002-01-03
US20040109878A1 (en) 2004-06-10
AU2001279264B2 (en) 2005-04-28
ZA200300016B (en) 2004-01-22
CA2412493A1 (en) 2002-01-03
AU7926401A (en) 2002-01-08
JP5208343B2 (ja) 2013-06-12
EP1297121B1 (en) 2005-05-04
IL153570A0 (en) 2003-07-06
US20070141033A1 (en) 2007-06-21
HK1052950A1 (en) 2003-10-03
EP1297121A2 (en) 2003-04-02
JP2004501200A (ja) 2004-01-15
CA2412493C (en) 2010-11-09
JP2013075921A (ja) 2013-04-25

Similar Documents

Publication Publication Date Title
IL153570A0 (en) Purging of cells using viruses
WO2007067280A3 (en) Very small embryonic-like (vsel) stem cells and methods of isolating and using the same
MXPA03006699A (es) Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias.
IL159637A0 (en) Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
EA200401467A1 (ru) Пептиды, полученные из казеина, и их применение в терапии
WO2004104166A3 (en) Administration of hyaluronic acid to enhance the function of transplanted stem cells
MY136635A (en) Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
DK1131096T3 (da) Anti-CD20-antistofbehandling af patienter, der modtager knoglemarvs- eller periferisk blodstamcelletransplantationer
IL161591A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2009059032A3 (en) Uses and isolation of very small embryonic-like (vsel) stem cells
DE60229848D1 (de) - und organtransplantationen und unterdrückt apoptose
WO1999043286A3 (en) Isolated stromal cells for use in the treatment of diseases of the central nervous system
CA2502394A1 (en) Surgical articles
WO2003012060A3 (en) Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
WO2001094541A3 (en) Human mesenchymal progenitor cell
HUS1900041I1 (hu) Treoszulfán alkalmazása betegek csontvelõ- és vér õssejt-transzplantáció elõtti kondicionálására
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
HK1023599A1 (en) Cells for preventing graft rejection in transplantation and their uses.
AP2003002785A0 (en) Treatment of t cell disorders
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
WO2003029432A3 (en) Human mesenchymal progenitor cell
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
WO2001094586A3 (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
DE69334227D1 (de) Hämatopoetische "facilitatory"-zellen und ihre verwendung

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130626